Loading clinical trials...
Loading clinical trials...
The purpose of the study is to evaluate the effect of VX-407 on height-adjusted total kidney volume (htTKV), safety, tolerability, and pharmacokinetics (PK) of VX-407.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Vertex Pharmaceuticals Incorporated
NCT07454174 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06594367 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06289998 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT07181265 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT02616055 · Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Alabama Kidney Research
Alabaster, Alabama
UAB Nephrology Research at CH19
Birmingham, Alabama
Kaiser Permanente Los Angeles Medical Center
Los Angeles, California
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions